Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today
Vivos Therapeutics Inc (NASDAQ:VVOS) shares are trading lower by 26.1% to $3.05 during Thursday’s session after the company announced a $4.3 million registered offering of 1.36 million shares of common stock at $3.
TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering
Vivos Therapeutics (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) in adults),
Vivos Therapeutics Inc (VVOS) Stock: More Resilient Than It Appears
In recent trading, Vivos Therapeutics Inc (VVOS) stock price has shown some volatility, fluctuating 4.41% over the last five trades and 8.57% over the past 30 trades. This represents a notable shift from earlier in the year.
Vivos Therapeutics Offers Of 1.363 Mln Shares At $3.15/share, Pre-Market Stock Down
Vivos Therapeutics, Inc. (VVOS), a medical device and technology company, announced on Thursday that it has inked a deal with
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
LITTLETON, Colo., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the ...
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering
Vivos Therapeutics shares dropped Thursday after the company said it is offering 1.4 million common shares at $3.15 per share in a registered direct offering. Shares were down 27% to $3.03 in recent trading after closing at $4.
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
The gross proceeds to the Company from the offering are expected to be approximately $4.3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering for working capital and general corporate purposes.
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children
On Wednesday, the FDA granted 510(k) clearance to Vivos Therapeutics, Inc.’s (NASDAQ:VVOS) flagship oral medical device, ...
Vivos surges on FDA nod for pediatric sleep apnea device
Vivos Therapeutics (VVOS) stock gains as company receives FDA clearance for its DNA appliance to treat obstructive sleep ...
bovnews4d
Vivos Therapeutics (VVOS) Surges Following Landmark FDA Approval
Vivos Therapeutics is a pioneering medical device and technology company focused on addressing sleep-related breathing disorders (SRBDs), particularly obstructive sleep apnea (OSA). Their flagship ...
Benzinga.com3d
Vivos Therapeutics (NASDAQ:VVOS) Stock, Short Interest Report
Short interest in Vivos Therapeutics Inc (NASDAQ:VVOS) decreased during the last reporting period, falling from 58.82K to 56.53K. This put 2.28% of the company's publicly available shares short.
Seeking Alpha26d
VVOS Vivos Therapeutics, Inc.
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.